Dr. Gillison

HPV related oral cancers continue to increase in the US

Source: International Medicine News CHICAGO – Human papillomavirus infection was firmly linked to the recent rise in oropharyngeal cancers in the United States, based on data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program. If current trends continue, the incidence of HPV-related oral cancers will soon surpass that of cervical cancers, senior author Dr. Maura Gillison reported at the annual meeting of the American Society of Clinical Oncology. The incidence of HPV-positive oropharyngeal cancers increased 225% – from 0.8 per 100,000 to 2.8 per 100,000 – between 1988 and 2004, the researchers found. At the same time, the incidence rate for HPV-negative oropharyngeal cancers, which are strongly related to tobacco and alcohol use, declined by 50% – from 2.0 per 100,000 to 1.0 per 100,000. Consequently, the overall incidence of oropharyngeal cancers increased 28%. Even by the conservative estimate that 70% of oropharyngeal cancers in 2020 will be HPV positive, the annual number of HPV-positive oral squamous cell carcinomas (8,653 cases) is expected to surpass cervical cancers (7,726 cases). Further, the majority will occur among men (7,426 cases), said Dr. Gillison, a medical oncologist and the Jeg Coughlin Chair in Cancer Research at Ohio State University Comprehensive Cancer Center in Columbus. Changes in sexual behavior among recent birth cohorts and increased oral HPV exposure probably influenced the increases in incidence and prevalence, Dr. Gillison speculated. Having a high lifetime number of sexual partners is a known risk factor for HPV infection. Although the rise in oral cancers [...]

Oral Cancer Foundation News Team - A2011-06-06T10:23:24-07:00June, 2011|Oral Cancer News|

Jeg Coughlin Sr. Chair filled by OSU’s Gillison

Source: Go2geiger.com Author: News Staff Leading human papilloma virus (HPV) expert Maura Gillison, MD, PhD, was officially named to the Jeg Coughlin Sr. Chair in Cancer Research during a special ceremony Wednesday night at the Longaberger Alumni House at The Ohio State University. "This is a dream come true for all of us," said Coughlin, who was surrounded by his four sons and many members of the extended Coughlin family. "This Chair represents a legacy that will continue forever. Cancer research takes commitment from a financial aspect and more importantly from a research and development side. Dr. Gillison has accomplished so many things already and we truly feel the best is yet to come." Gillison recently joined OSU's staff after a successful stint as associate professor at Johns Hopkins University School of Medicine in Baltimore, Md., where she was a member of the Sidney Kimmel Comprehensive Cancer Center. She now serves as professor of medicine in the division of hematology and oncology at OSU and is a member of the Cancer Control and Viral Oncology Programs at the Comprehensive Cancer Center. "Unfortunately, like so many other families, the Coughlins have been touched by cancer," Gillison said. "Now, they are a family on a mission. They put the same enthusiasm they bring to racing into cancer research. The Coughlin family has made it possible for me to take my research into a much broader direction and to really think outside of the box." Focusing on the role that [...]

Charlotte Parker2009-05-29T09:37:54-07:00May, 2009|Oral Cancer News|

ASCO: HPV Infection Linked to Better Outcome in Oropharyngeal Cancer

Source: MedpageToday.com Author: Michael Smith TORONTO, May 14 -- Patients with oropharyngeal cancer had a 50% lower five-year mortality risk when they also had human papillomavirus (HPV) infection, according to data from a randomized clinical trial. HPV-positive patients had a two-year overall survival of 88% compared with 66% for HPV-negative patients (P<0.001), said Maura Gillison, M.D., of Ohio State University in Columbus. The difference between groups increased with follow-up. HPV infection also was associated with a reduced risk of locoregional recurrence and second cancers, Dr. Gillison reported at a press briefing in advance of the American Society of Clinical Oncology annual meeting. Cancer of the oropharynx arises from two principal causes: chronic use of tobacco and alcohol or HPV infection. Previous studies had suggested that HPV status of a patient's tumor might have prognostic implications. "HPV-positive patients have important associations with other favorable prognostic factors," said Dr. Gillison. "They tend to be younger; they have smaller tumors; they present with better performance status. Therefore, improvement in survival for this patient population may be explained by these factors and not by HPV." To explore the role of HPV status in survival of oropharyngeal cancer, Dr. Gillison and colleagues reviewed data from a randomized clinical trial conducted by the Radiation Therapy Oncology Group. Its principal objective was to compare standard chemotherapy with an investigational regimen. The trial involved 721 patients. Of those, 60% had cancer of the oropharynx and 64% were HPV positive. The two-year results demonstrated a clear survival advantage associated [...]

Charlotte Parker2009-05-15T16:11:18-07:00May, 2009|Oral Cancer News|